New benchmark set to deliver optimal osteoporosis care throughout Asia Pacific

The Asia Pacific Consortium on Osteoporosis (APCO) has today (Thursday, January 28, 2021) launched the first pan-Asia Pacific clinical practice standards for the screening, diagnosis, and management of osteoporosis, targeting a broad range of high-risk groups.

Published in Osteoporosis International today, ‘The APCO Framework’ comprises 16 minimum clinical standards set to serve as a benchmark for the provision of optimal osteoporosis care in the region.

Developed by APCO members representing key osteoporosis stakeholders, and multiple medical and surgical specialities, this set of clear, concise, relevant and pragmatic clinical standards aims to support national societies, guidelines development authorities, and health care policy makers with the development of new guidelines, and to encourage the revision of existing guidelines.

According to the Framework lead author, APCO Chairperson, and Director of the Osteoporosis and
Bone Metabolism Unit at Singapore General Hospital, Dr Manju Chandran, Singapore, APCO employed a
5IQ analysis and the well-established Delphi Consensus process to analyse the 18 clinical practice guidelines currently available in the Asia Pacific region, to inform the development of The APCO Framework.

“Utilising a comprehensive, four-round Delphi consensus method enabled our APCO members who work in vastly different health care systems, to reach a remarkable level of consensus on a benchmark set of clinical standards for the provision of quality osteoporosis care for the Asia Pacific region.”

The APCO Framework offers clinicians structured, well-articulated, and readily accessible clinical practice guidelines that define:
o Individuals to be identified for assessment;
o Investigations required;
o Relevant indications for treatment;
o Appropriate selection of interventions to be made;
o The guidance and information patients need for self-care;
o Integration of healthcare systems for optimal provision of care; and
o The need, and methods for monitoring and improving the quality of osteoporosis care.

“Implementation of The APCO Framework, or a similar set of standards of care informed by the Framework, is expected to significantly reduce the burden of osteoporosis not only in the Asia Pacific region, but also worldwide. We hope that the Framework can serve as a stimulus for harmonisation of guidelines in other regions that have similar socio-economic diversity and heterogeneity of health care resources,” Dr Chandran said.

Globally, the population aged 65 years or over increased from six per cent in 1990, to nine per cent in 2019.(1)
This proportion is projected to rise to 16 per cent by 2050,(1) meaning one in six people worldwide will be aged
65 years or over by 2050.(1) The number of people aged 60 years and over in the Asia-Pacific region – home to
more than a third of the world’s population aged 65 years and over, and to more elderly people than any other region(2) – is predicted to triple between 2010 and 2050, reaching a staggering 1.3 billion people.(3)

Osteoporotic fractures among Asia-Pacific populations are expected to increase exponentially, not only because of the region’s rapidly aging population, but also due to mounting urbanisation, and the subsequent increase in sedentary lifestyles.(4)

Despite the presence of generally safe and effective treatments for osteoporosis, as many as five in six patients presenting to their primary care physician (PCP), or to a hospital with a fragility fracture, will not be assessed for osteoporosis, nor appropriately managed to prevent further fracture.(5)

According to Medical Director of Osteoporosis Australia, and APCO Executive Committee member,
Professor Peter Ebeling AO, Australia, as many as half of those who have sustained a hip fracture, have already experienced a previous fracture at other skeletal sites.

“In fact, a prior fracture at any site is associated with a doubling of future fracture and mortality risk. The unfortunate ramifications of the gross under-diagnosis and under-treatment of osteoporosis is that a large number of people sustain further debilitating secondary fractures, which places a substantial, but importantly, preventable burden on already strained healthcare systems,” said Prof Ebeling.

A fragility fracture, which occurs every three seconds worldwide,(6) compromises quality of life and loss of independence.(6),(7) Concerningly, one-in-four patients who sustain a hip fracture die within a year, and less than half of those who survive, regain their previous level of function.(8),(9) In 2010, an estimated 158 million people aged
50 years and above were at high risk for osteoporotic fracture – a figure which is set to double by 2040.(10)

According to International Osteoporosis Foundation (IOF) CEO and APCO Executive Committee member,

Dr Philippe Halbout, Switzerland, these alarming statistics, coupled with the anticipated, exponential rise in osteoporotic fractures among Asia-Pacific populations, warrant a standardised set of minimum clinical standards for the region.

“Anecdotal evidence to date reveals significant inconsistencies in osteoporosis clinical practice guidelines in the Asia Pacific region, which vary widely in scope and recommendations. This was confirmed when we analysed the 18 guidelines.

“Implementation of the minimum clinical standards proposed by The APCO Framework, and reform of existing guidelines, will support clinical improvement initiatives, while also paving the way for a more holistic approach to osteoporosis care, and ultimately, greater consistency across all national and regional clinical practice guidelines in the region,” Dr Halbout said.

To download or access The APCO Framework, head to www.apcobonehealth.org/apco-framework

To learn more, visit www.apcobonehealth.org or follow APCO on LinkedIn: asia-pacific-consortium-on-osteoporosis

About APCO

The Asia Pacific Consortium on Osteoporosis (APCO) comprises osteoporosis experts from several countries and regions in the Asia Pacific, charged with developing tangible solutions to the substantive challenges involving osteoporosis management and fracture prevention in this most populated and fastest growing part of the world. APCO’s mission is to engage with relevant stakeholders, including healthcare providers, policy makers and the public, to help develop and implement country and region-specific programs for the prevention and treatment of osteoporosis, and its complication of fragility fractures, in the Asia Pacific.

About IOF

The International Osteoporosis Foundation (IOF) is the world’s largest non-governmental organisation dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF’s mission is to promote bone and musculoskeletal health as a worldwide priority.

The 5IQ analysis and Delphi consensus process

The 5IQ exercise assessed the extent of disparity when comparing the national guidelines currently available throughout the Asia Pacific region.

The Delphi technique (a structured communication technique using a systematic, interactive forecasting method reliant upon an expert panel) was employed to achieve APCO member consensus for the development of clinical standards of care.(11)

EXPERTS AVAILABLE FOR INTERVIEW

Dr Manju Chandran – APCO Executive Committee Chairperson, Senior Consultant, Department of Endocrinology, Director, Osteoporosis & Bone Metabolism Unit, Singapore General Hospital, SINGAPORE

Dr Philippe Halbout – Chief Executive Officer (CEO), International Osteoporosis Foundation (IOF), APCO Executive Committee member, SWITZERLAND

Prof. Peter Ebeling AO – Medical Director, Osteoporosis Australia & APCO Executive Committee member, AUSTRALIA

Dr Zhao Yanling – Obstetrician & Gynaecologist, Beijing United Family Hospital, & APCO Member, Beijing, CHINA

Prof. Atsushi Suzuki – Professor & Chair, Department of Endocrinology & Metabolism, Fujita Health University & APCO Member, JAPAN

Prof. Yoon-Sok Chung – Professor, Department of Endocrinology & Metabolism, Director, Ajou Institute on Aging, Ajou University Medical Center & APCO Member, SOUTH KOREA

Dr Hew Fen Lee – Consultant Endocrinologist, Puchong Medical Specialist Centre, Subang Jaya Medical Centre & APCO member, MALAYSIA

Dato’ Dr. Lee Joon-Kiong – Consultant Orthopaedic Surgeon, Beacon Hospital & APCO Member, MALAYSIA

Dr Nigel Gilchrist – Specialist Consultant Physician, Canterbury District Health Board & APCO ExecutiveCommittee Member, Christchurch, NEW ZEALAND

Mr Paul Mitchell – Adjunct Senior Lecturer, School of Medicine, University of Notre Dame Australia & APCO Executive Committee Member, Auckland, NEW ZEALAND

MEDIA CONTACTS & INTERVIEWS

Kirsten Bruce & Mel Kheradi, VIVA! Communications, Sydney, Australia
T +61 (0)401 717 566; +61 (0)421 551 257
E: kirstenbruce@vivacommunications.com.au; mel@vivacommunications.com.au

DOWNLOAD THE APCO FRAMEWORK DIGITAL MEDIA KIT: www.apcoframeworkmediakit.org


References:
(1) United Nations – Department of Economic and Social Affairs, World Population Ageing 2019 Highlights. 2019.
(2) World Bank Group, Live Long and Prosper – Aging in East Asia and Pacific. 2016.
(3) United National Population Fund (UNFPA) Asia & the Pacific. Ageing. [cited Nov, 2020]; Available from: https://asiapacific.unfpa.org/en/node/15208.
(4) International Osteoporosis Foundation, The Asia-Pacific Regional Audit: Epidemiology, costs & burden of osteoporosis in 2013. 2013. p. 1-128.
(5) Royal Australian College of General Practitioners & Osteoporosis Australia, Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. 2017.
(6) International Osteoporosis Foundation (IOF). Capture the fracture. [cited Jan, 2020]; Available from: https://www.capturethefracture.org/about.
(7) Madureira, M.M., R.M. Ciconelli, and R.M.R. Pereira, Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo, Brazil), 2012. 67(11): p. 1315-1320.
(8) National Osteoporosis Foundation, NOF’s Clinician’s Guide to Prevention and Treatment of Osteoporosis.
(9) Australian Institute of Health and Welfare. Musculoskeletal fact sheet. Osteoporosis. [cited Jan, 2020]; Available from: https://bit.ly/3qQOqbi
(10) Oden, A., et al., Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int, 2015. 26(9): p. 2243-8.
(11) Royal College of Obstetricians and Gynaecologists. The Delphi technique. 2005 [cited Jan, 2020]; Available from: https://bit.ly/39hWags



Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Lasting Antiviral Effect against Covid-19 virus (SARS-CoV-2) by TAKEX CLEAN EXTRA

Osaka, Japan, Jan 27, 2021 – (ACN Newswire) – Takex Co., Ltd. (Suita City, Osaka Prefecture / President and CEO: Kumi Okada), a company engaged in the research and development of bamboo for 34 years after the development of a sanitizer using bamboo extract in 1987, announces the result of verification test on TAKEX CLEAN EXTRA (bamboo extract-containing ethanol sanitizer) against Covid-19 virus (SARS-CoV-2) and confirms a 99.99% virus inactivation, even after 15 days.

TAKEX CLEAN EXTRA used in this test is a food-grade ethanol sanitizer containing extract from bamboo sheath. It also provides assurance to the users as TAKEX CLEAN EXTRA is Halal certified by JAKIM, the Malaysian government certification body, which is recognized in other countries as well. TAKEX CLEAN EXTRA is manufactured in Kuala Lumpur and now on sale in Malaysia, Singapore & Indonesia (product name: MAZTEX CLEAN EXTRA) and Thailand (product name: TAKETSUYU).

Takex will continue to create products which contribute to people's health and safety through research and development in bamboo.

Summary and results of the evaluation test:

I. Covid-19 virus strain used in the test
SARS-CoV-2 JPN/TY/WK-521 (Provided by National Institute of Infectious Diseases)

II. Test summary
– Test center: Japan Texile Products Quality and Technology Center
– Test sample: TAKEX CLEAN EXTRA (Bamboo extract-containing ethanol preparation)
– Operative temperature: 25 degrees C
– Measurement of infectivity titer: Plaque assay
– Date of preparation of test specimen: December 3, 2020
– Date of testing: December 18, 2020

III. Test method
1. Apply the test sample on 50mm x 50mm plates and dry them. Store the plates for 15 days to use as test specimens.
2. Inoculate 0.40ml of the test virus inoculum onto the 15 day-old test specimens.
3. After covering with a PE film (40mm x 40mm) and contacting at 25 degrees C and relative humidity of not less than 90% for 24 hours, add 10ml of wash-out solution onto each specimen.
4. Rub the surface of each specimen and film to wash out the virus.
5. Determine the virus infectivity titer by plaque assay.

IV. Test result
It is confirmed that 99.99% of the virus was inactived after 15 days of TAKEX CLEAN EXTRA application.

V. Test standard
ISO21702

What is Bamboo extract?
Bamboo extract is obtained from the crushed sheath of a stem of gramineous Moso bamboo grown in Japan, using a special extraction method. Bamboo is approved in Japan as a food additive by the Ministry of Health, Labor and Welfare, confirming its safety.

Takex confirmed in research with Osaka Prefecture University that Bamboo extract was effective to inactivate feline calicivirus, an alternative virus of norovirus, which is one of the agents of food poisoning. Also, in another research with Tottori University, it confirmed that the extract was effective to inactivate bird flu virus (H5N3).

About Takex Co., Ltd.
Takex has been developing, manufacturing and selling hygiene products and shelf-life improvement agents containing active ingredients extracted from bamboo since it developed a sanitizer using Bamboo extract in 1987. Targeting not only the Japanese market, but overseas and Halal markets as well, Takex offers antibacterial and sanitizing agents, freshness-keeping agents, food additives, and other products which obtain halal market certification by Malaysia's JAKIM. Please visit https://takex-co.com/en/

Takexco Malaysia Sdn. Bhd. is a subsidiary of Takex Co., Ltd. established in Malaysia in September 2017.

For the Covid-19 virus test and detailed product information, please see the attached reference document: http://www.acnnewswire.com/pdf/files/Takex.pdf

Thailand Distributor contact:
Best Provider Co., Ltd
45 Moo 3 Tumbon Ladbualuang, Aumpur Ladbualuang,
Ayutthaya Province, 13230 Thailand
E-Mail: bestprovider2017@gmail.com
Telephone: (+66) 64-262-8939, (+66) 93-965-5697, (+66) 86-388-4581
Facebook: Taketsuyu by takexco – https://www.facebook.com/Taketsuyu.TH/
Official Instagram: Taketsuyu_by_takexco
Line: @193wzfsq

Media contact:
Takex PR office (within Kyodo PR)
E-mail: takex-pr@kyodo-pr.co.jp

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Lasting Antiviral Effect against Covid-19 virus (SARS-CoV-2) TAKEX CLEAN EXTRA

Osaka, Japan, Jan 27, 2021 – (ACN Newswire) – Takex Co., Ltd. (Suita City, Osaka Prefecture / President and CEO: Kumi Okada), a company engaged in the research and development of bamboo for 34 years after the development of a sanitizer using bamboo extract in 1987, announces the result of verification test on TAKEX CLEAN EXTRA (bamboo extract-containing ethanol sanitizer) against Covid-19 virus (SARS-CoV-2) and confirms a 99.99% virus inactivation, even after 15 days.

TAKEX CLEAN EXTRA used in this test is a food-grade ethanol sanitizer containing extract from bamboo sheath. It also provides assurance to the users as TAKEX CLEAN EXTRA is Halal certified by JAKIM, the Malaysian government certification body, which is recognized in other countries as well. TAKEX CLEAN EXTRA is manufactured in Kuala Lumpur and now on sale in Malaysia, Singapore & Indonesia (product name: MAZTEX CLEAN EXTRA) and Thailand (product name: TAKETSUYU).

Takex will continue to create products which contribute to people's health and safety through research and development in bamboo.

Summary and results of the evaluation test:

I. Covid-19 virus strain used in the test
SARS-CoV-2 JPN/TY/WK-521 (Provided by National Institute of Infectious Diseases)

II. Test summary
– Test center: Japan Texile Products Quality and Technology Center
– Test sample: TAKEX CLEAN EXTRA (Bamboo extract-containing ethanol preparation)
– Operative temperature: 25 degrees C
– Measurement of infectivity titer: Plaque assay
– Date of preparation of test specimen: December 3, 2020
– Date of testing: December 18, 2020

III. Test method
1. Apply the test sample on 50mm x 50mm plates and dry them. Store the plates for 15 days to use as test specimens.
2. Inoculate 0.40ml of the test virus inoculum onto the 15 day-old test specimens.
3. After covering with a PE film (40mm x 40mm) and contacting at 25 degrees C and relative humidity of not less than 90% for 24 hours, add 10ml of wash-out solution onto each specimen.
4. Rub the surface of each specimen and film to wash out the virus.
5. Determine the virus infectivity titer by plaque assay.

IV. Test result
It is confirmed that 99.99% of the virus was inactived after 15 days of TAKEX CLEAN EXTRA application.

V. Test standard
ISO21702

What is Bamboo extract?
Bamboo extract is obtained from the crushed sheath of a stem of gramineous Moso bamboo grown in Japan, using a special extraction method. Bamboo is approved in Japan as a food additive by the Ministry of Health, Labor and Welfare, confirming its safety.

Takex confirmed in research with Osaka Prefecture University that Bamboo extract was effective to inactivate feline calicivirus, an alternative virus of norovirus, which is one of the agents of food poisoning. Also, in another research with Tottori University, it confirmed that the extract was effective to inactivate bird flu virus (H5N3).

About Takex Co., Ltd.
Takex has been developing, manufacturing and selling hygiene products and shelf-life improvement agents containing active ingredients extracted from bamboo since it developed a sanitizer using Bamboo extract in 1987. Targeting not only the Japanese market, but overseas and Halal markets as well, Takex offers antibacterial and sanitizing agents, freshness-keeping agents, food additives, and other products which obtain halal market certification by Malaysia's JAKIM. Please visit https://takex-co.com/en/

Takexco Malaysia Sdn. Bhd. is a subsidiary of Takex Co., Ltd. established in Malaysia in September 2017.

For the Covid-19 virus test and detailed product information, please see the attached reference document: http://www.acnnewswire.com/pdf/files/Takex.pdf

Thailand Distributor contact:
Best Provider Co., Ltd
45 Moo 3 Tumbon Ladbualuang, Aumpur Ladbualuang,
Ayutthaya Province, 13230 Thailand
E-Mail: bestprovider2017@gmail.com
Telephone: (+66) 64-262-8939, (+66) 93-965-5697, (+66) 86-388-4581
Facebook: Taketsuyu by takexco – https://www.facebook.com/Taketsuyu.TH/
Official Instagram: Taketsuyu_by_takexco
Line: @193wzfsq

Media contact:
Takex PR office (within Kyodo PR)
E-mail: takex-pr@kyodo-pr.co.jp

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Lasting Antiviral Effectiveness against Covid-19 virus (SARS-CoV-2) by TAKEX CLEAN EXTRA

Osaka, Japan, Jan 27, 2021 – (ACN Newswire) – Takex Co., Ltd. (Headquarters: Suita City, Osaka Prefecture / President and CEO: Kumi Okada), engaged in the research and development of bamboo extract in sanitizer for 34 years since 1987. A lab test was conducted with TAKEX CLEAN EXTRA SANITIZER against Covid-19 virus (SARS-CoV-2). Positive result shown 99.99% of the virus inactivation even after 15 days.

TAKEX CLEAN EXTRA is a food grade ethanol sanitizer containing Bamboo extract. It provides assurance for users as TAKEX CLEAN EXTRA is Halal certified by JAKIM, Malaysia government certification body which is highly recognized in other countries. TAKEX CLEAN EXTRA is manufactured in Kuala Lumpur, Malaysia and now on sale in Malaysia, Singapore, Indonesia (Product name is MAZTEX CLEAN EXTRA) and Thailand (Product name is TAKETSUYU).

Takex pledges to develop products which contribute to the health and safety of users through continuous research and development of bamboo.

Summary and result of the evaluation test

[Covid-19 virus strain used for the test]
SARS-CoV-2 JPN/TY/WK-521 (Provided by National Institute of Infectious Diseases)

[Summary of test]
– Test center: Japan Textile Products Quality and Technology Center
– Test sample: TAKEX CLEAN EXTRA (Bamboo extract-containing ethanol preparation)
– Operative temperature: 25 degrees C
– Measurement of infectivity titer: Plaque assay
– Date of preparation of test specimen: December 3, 2020
– Date of testing: December 18, 2020

[Test method]
1. Apply the test sample on 50mm x 50mm plates and dry them. Store the plates for 15 days to use as test specimens.
2. Inoculate 0.40ml of the test virus inoculum onto the 15 days-old test specimens.
3. After covering with a PE film (40mm x 40mm) and contacting at 25 degrees C and a relative humidity of not less than 90% for 24 hours, add 10ml of wash-out solution onto each specimen.
4. Rub the surface of each specimen and film to wash out the virus.
5. Determine the virus infectivity titer by plaque assay.

[Test result]
99.99% of the virus became inactive even after 15 days of TAKEX CLEAN EXTRA application.

[Test standard]
ISO21702

What is Bamboo extract
Bamboo extract is obtained from the crushed sheath of the stem of a gramineous Moso bamboo grown in Japan using unique extraction method. It is approved as a food additive in Japan under Japan government – Ministry of Health, Labor and Welfare, which confirmed the safety of bamboo.

In a collaboration research with Osaka Prefecture University, lab test result shown Bamboo extract is effective to inactivate feline calicivirus, a type of norovirus which is responsible for food poisoning. In addition, in another collaboration research with Tottori University, lab test result also shown the bamboo extract is effective to inactivate a bird flu virus (H5N3).

About Takex Co., Ltd. https://takex-co.com/en/
Takex has been developing, manufacturing and selling hygiene products and shelf-life improvement agents that contain active ingredients extracted from bamboo since it started in 1987. Serving not only the Japan market but also Halal and non-Halal markets around the world. Takex offers antibacterial and sanitizing agents, freshness-keeping agents, food additives, which had obtained halal certifications by JAKIM, Malaysia in the halal market.

Takexco Malaysia Sdn. Bhd. is a subsidiary company of Takex Co., Ltd. in Malaysia, which was established in September 2017. For the Covid-19 virus test and products detailed information, please refer attached reference document. http://www.acnnewswire.com/pdf/files/Takex.pdf

Distributor in Singapore
Sze Heng Chan Holdings Pte. Ltd.
1 Tampines North Drive 1
#06-17/18/19 T Space
Singapore 528559
Lester +65 9666 7775
Carmen +65 8587 9889
Email: takex@szehengchan.com
www.facebook.com/szehengchanholdingspteltd

Media contact
Takex PR office (within Kyodo PR)
E-mail takex-pr@kyodo-pr.co.jp

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Lasting Antiviral Effect against Covid-19 virus (SARS-CoV-2) by TAKEX CLEAN EXTRA

Osaka, Japan, Jan 26, 2021 – (ACN Newswire) – Takex Co., Ltd. (Headquarters: Suita City, Osaka Prefecture / President and CEO: Kumi Okada), the company engaged in the research and development of bamboo for about 34 years since the development of a sanitizer by using bamboo extract in 1987, announces that it has conducted a verification test of TAKEX CLEAN EXTRA Sanitizer against Covid-19 virus (SARS-CoV-2) and confirmed 99.99% of the virus inactivation even after 15 days.

TAKEX CLEAN EXTRA Sanitizer used for this test is a food grade ethanol sanitizer containing Bamboo extract, extracted from bamboo skin. It also provides assurance for the users as TAKEX CLEAN EXTRA is Halal certified by JAKIM, Malaysia government certification body which is highly recognized in other countries as well. TAKEX CLEAN EXTRA is manufactured in Kuala Lumpur, Malaysia and now on sale in Malaysia, Singapore, Indonesia (Product name is MAZTEX CLEAN EXTRA) and Thailand (Product name is TAKETSUYU).

Takex will continue to create products which contribute to the health and safety of people through the research and development of bamboo.

Summary and result of the evaluation test

[Covid-19 virus strain used for the test]
SARS-CoV-2 JPN/TY/WK-521 (Provided by National Institute of Infectious Diseases)

[Summary of test]
– Test center: Japan Textile Products Quality and Technology Center
– Test sample: TAKEX CLEAN EXTRA (Bamboo extract-containing ethanol preparation)
– Operative temperature: 25 degrees C
– Measurement of infectivity titer: Plaque assay
– Date of preparation of test specimen: December 3, 2020
– Date of testing: December 18, 2020

[Test method]
1. Apply the test sample on 50mm x 50mm plates and dry them. Store the plates for 15 days to use as test specimens.
2. Inoculate 0.40ml of the test virus inoculum onto the 15 days-old test specimens.
3. After covering with a PE film (40mm x 40mm) and contacting at 25 degrees C and a relative humidity of not less than 90% for 24 hours, add 10ml of wash-out solution onto each specimen.
4. Rub the surface of each specimen and film to wash out the virus.
5. Determine the virus infectivity titer by plaque assay.

[Test result]
It is confirmed that 99.99% of the virus became inactive after 15 days of TAKEX CLEAN EXTRA application.

[Test standard]
ISO21702

What is Bamboo extract
Bamboo extract is obtained from the crushed sheath of the stem of a gramineous Moso bamboo grown in Japan using special extraction method. It is approved as a food additive in Japan under Ministry of Health, Labor and Welfare, which confirm the safety of itself.

Takex confirmed in a research with Osaka Prefecture University that Bamboo extract was effective to inactivate feline calicivirus, an alternative virus of norovirus which is one of the agents of food poisoning. Also, in another research with Tottori University, it confirmed that the extract was effective to inactivate a bird flu virus (H5N3).

About Takex Co., Ltd. https://takex-co.com/en/
Takex has been developing, manufacturing and selling hygiene products and shelf-life improvement agents that contain active ingredients extracted from bamboo since it developed a sanitizer using Bamboo extract in 1987. Targeting not only the Japanese market but also overseas and Halal markets, Takex is offering antibacterial and sanitizing agents, freshness-keeping agents, food additives, and others which obtain halal certification by JAKIM, Malaysia in the halal market.

Takexco Malaysia Sdn. Bhd. is a subsidiary company of Takex Co., Ltd. in Malaysia, which was established in September 2017. For the Covid-19 virus test and products detailed information, please refer attached reference document. http://www.acnnewswire.com/pdf/files/Takex.pdf

Takexco Malaysia Sdn Bhd. Contact information
Unit 06-08, Level 6, Menara MBMR,
No.1, Jalan Syed Putra,
58000 Kuala Lumpur, Malaysia.
Tel: 03-27323986
admintm@takex-co.com

Media contact
Takex PR office (within Kyodo PR)
E-mail: takex-pr@kyodo-pr.co.jp

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited

HONG KONG, Jan 25, 2021 – (ACN Newswire) – JBM (Healthcare) Limited ("JBM Healthcare" or "Company" and, together with its subsidiaries, the "Group"), a Hong Kong-based company that markets and distributes branded healthcare products with product footprint across Greater China, Southeast Asia and certain other countries, today announced details of the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK").



Mr. Patrick Wong, Chief Executive Officer and Executive Director of JBM Healthcare (left) and Dr. Chu Ka Wing, President of the Proprietary Chinese Medicine Business and Executive Director of JBM Healthcare (right)



Highlights
– The fourth largest brand operator that carries both over-the-counter ("OTC") proprietary medicines and OTC proprietary Chinese medicines in Hong Kong in 2019 by revenue
– As a subsidiary of Jacobson Pharma Corporation Limited ("Jacobson Pharma"; Stock Code: 2633), JBM Healthcare is a unique field player with drug expertise and a heritage that continues to foster a corporate culture of prioritizing product efficacy and quality
– Notable and growing brand portfolio along with a proven brand management capability. As at March 31, 2020, JBM Healthcare carried a total of 20 principal brands, including 11 third-party brands and 9 own brands
– Extensive sales and distribution network in Hong Kong, with a geographical reach spanning over China, Macau, Taiwan and select countries in Southeast Asia, Europe, North America and the Caribbean Islands

Jacobson Pharma indirectly holds 85.04% of JBM Shares. Upon completion of the proposed spin-off, Jacobson Pharma will hold not less than 50% of the shares of JBM Healthcare ("JBM Shares") and that JBM Healthcare will remain a subsidiary of Jacobson Pharma with its results continue to be consolidated into the accounts of Jacobson Parma. Jacobson Pharma will effect a distribution in specie of a portion of its JBM Shares if the spin-off proceeds, where each qualifying shareholder of Jacobson Pharma will be entitled to one JBM Share for every eight shares of Jacobson Pharma held.

JBM Healthcare has received pre-IPO Investments from three strategic investors, namely New Heritage Healthcare Limited, who was one of the cornerstone investors of Jacobson Pharma during its global offering in 2016 and an existing shareholder of Jacobson Pharma; Gold Century Assets Limited, which its wholly-owned subsidiary Kin Fung Weisen-U Company Limited, a joint venture partner of the Group; and Profit Cape Limited, an indirect wholly-owned subsidiary of Tycoon Group Holdings Limited (Stock Code: 3390), a company listed on the Main Board of the Stock Exchange who is also JBM Healthcare's Hong Kong distributor and the parent company of its joint venture partner in a jointly controlled entity. A total of 97,000,000 JBM Shares were issued pursuant to the pre-IPO investments, representing approximately 11.43% of the total issued JBM Shares immediately after completion of the pre-IPO investments, with an aggregate consideration of HK$97.0 million,

Offering Details
The Group intends to offer a total of 44,686,000 JBM Shares for the Public Offer. After deducting underwriting commissions and estimated expenses payable in connection with the Public Offer and assuming an offer price of HK$1.2 per Offer Share, net proceeds from the Public Offer are estimated to be approximately HK$10.6 million. China Galaxy International Securities (Hong Kong) Co., Limited is the Sole Sponsor of the listing.

The Hong Kong Public Offer will begin at 9:00 am on 26 January 2021 (Tuesday) and will end at 12:00 noon on 29 January 2021 (Friday). The allotment results will be announced on 4 February 2021 (Thursday). Dealing in JBM Healthcare's Shares will commence on the Main Board of SEHK on 5 February 2021 (Friday) under the stock code 2161. The shares will be traded in board lots of 2,000 shares each.

Investment Highlights
A leading Hong Kong-based brand operator with a notable and growing brand portfolio and proven brand management capability
The Group was the fourth largest brand operator that carries both OTC proprietary medicines and OTC proprietary Chinese medicines in Hong Kong in 2019 by revenue1. As at March 31, 2020, the Group carried a total of 20 principal brands, including 11 third-party brands and 9 own brands. Besides, the Group has established a track record of introducing category-leading overseas branded healthcare products to local markets and revitalized the brand positioning of its heritage household brands based on changing demographics and consumer behaviors. It is believed that its brand management capability is among the core competitive advantages in the branded healthcare market.

A unique field player with a heritage of pharmaceutical background and quality-driven culture of Jacobson Pharma
As a subsidiary of Jacobson Pharma, a leading generic drug company in Hong Kong in 20191, the Group is a unique field player with drug expertise and a heritage that continues to foster a corporate culture of prioritizing product efficacy and quality. It is believed that, leveraged on the ethical and trustworthy reputation and high market standing of the Jacobson Pharma in the pharmaceutical sector, it makes third-party brand owners and product originators are more inclined to choose to partner with the Group. In addition, with the high standard of quality control inherited from an ethical pharmaceutical company, JBM Healthcare is one of the few GMP-accredited proprietary Chinese medicine manufacturers in Hong Kong1. It is believed the long track record of providing reliable and quality products position the Group to capture any future market opportunities.

Dual engines of growth through sourcing and development of category-leading products and acquisitions of synergetic brands
Backed by a specialized product development team with relevant regional industry knowledge, the Group has a long proven track record of deploying dual engines to support its business developments. Not only organically growing its business through the in-depth understanding and clear vision of healthcare trends and categories with market space, as well as identifying product candidates or development with fitting allure and efficacy attributes. The Group also demonstrated the consistent ability to realize synergies through strategic acquisitions and investments, which are in line with its growth and business directions. It enables JBM Healthcare to expand its own brand portfolio successfully through acquisition and integration of attractive branded healthcare products.

Extensive sales and distribution network in Hong Kong with multi-region geographical reach
The Group has established an extensive sales and distribution network in Hong Kong, with a geographical reach spanning over China, Macau, Taiwan and select countries in Southeast Asia, Europe, North America and the Caribbean Islands. The stable business relationships with key retailers and the Hong Kong distributor, coupled with its reputation in delivering high quality products and the wide distribution network, have enabled JBM Healthcare to generate effective retail penetration and commercialization of its new products. Armed with a hybrid of sales and distribution models tailored for different products and geographic markets, It is believed that JBM Healthcare is well-positioned to leverage its geographical presence and develop a sustainable regional platform in Asia for branded healthcare products.

Seasoned management team with in-depth industry knowledge and regional experience
The Group's core management team comprises a group of technically seasoned industry veterans with a strong track record and proven execution capabilities. Vast majority of its directors and senior management team, who on average has approximately 25 years of relevant industry experience, are registered pharmacists or have pharmaceutical or medical academic backgrounds. It is believed that the experienced senior management team has been and will continue to be key to its success in deployment of its dual engines of growth, allowing the Group to further integrate its regional resources and take advantage of new opportunities.

Business Strategies
The PRC cross-border e-commerce market has grown rapidly as a result of the rising demand for overseas healthcare products and an increasingly structured and formalized cross-border e-commerce channel in the PRC market. According to Frost & Sullivan Report, the gross merchandise volume of pharmaceutical products e-commerce market in China is forecasted to reach HK$452.2 billion by 2024. The Group intends to expand its product offerings and deepen product penetration in China through cross-border e-commerce initiatives. In order to increase its product penetration to end consumers across all provinces, cities and counties in China and shorten its product launch time, the Group will continue to actively deploy efforts and resources in the development of cross-border e-commerce initiatives by broadening presence in cross-border e-commerce channels across a variety of popular platforms and engaging different cross-border e-commerce models. Besides, the Group intends to offer eligible branded health products through cross-border e-commerce channels while formulating integrated brand strategies to raise consumer awareness and profile of its brands and its own online store to support product launches and improve sales performance. The Group aims to optimize its online presence and enhance the visibility of its brand and products through multi-channel performance marketing initiatives, with the goal to increase the product penetration in the PRC market.

In addition, the Group will further expand its portfolio through organic growth and mergers and acquisitions in order to maintain its competitive position and ensure its future growth and success. While the Group will continue to seek organic growth for its product portfolio and adapt its product offerings and develop product line extensions by building on existing own brand products and their brand appeal, it also intends to pursue suitable opportunities to acquire synergistic businesses in line with its growth and business directions to enhance existing product portfolio and increase local presence in other key markets for its products and business.

Leveraging the Group's established local business relationships and networks, JBM Healthcare intends to develop a branded healthcare product sourcing and distribution platform in Asia through the integration of its regional resources and foothold. The Group sources third-party brand products and secure third-party manufacturing arrangements for selected products in Greater China and other select countries in Southeast Asia. In the short-term, the Group intends to leverage its established local business relationships and networks to further enhance the on-the-ground presence of its products through the establishment of joint venture and expansion of existing relationship. In particular, JBM Healthcare has established a joint venture with a renowned PRC state-owned conglomerate through a jointly controlled entity with its Hong Kong distributor and intend to increase its product penetration and explore other collaborative opportunities in China. For the long-term, the Group aims to strengthen its geographical reach in Southeast Asia and capture the growing demand for health and wellness products. The Group will seek to leverage on its track record in those strategic locations to further source and introduce new third-party brand products and eventually develop into a sustainable branded healthcare product sourcing and distribution platform in Asia.

Backed by an extensive network in Hong Kong, the Group intends to unleash the sales and distribution potential of its Chinese medicine practitioner network. It is believed that the direct access and frequent interaction with Chinese medicine practitioners in Hong Kong enables the Group to gain specific insights and understanding of their practices, preferences and operational environment. JBM Healthcare will seek to utilize such insights to capture new business opportunities and capitalize on this distribution channel.

Use of Proceeds
Assuming the Offer Price is HK$1.2 per Offer Share, the net proceeds are expected to be approximately HK$10.6 million, and the Group will apply such net proceeds for the following purposes:
Item / Percentage
To fund the portfolio development and brand management of proprietary Chinese medicines: 47.2%
To fund payments (upfront, in stages or otherwise) for obtaining additional distribution rights from third-party brand owners, as part of the strategy to grow third-party brand product portfolio: 43.4%
To supplement working capital and for general corporate purposes: 9.4%

About JBM (Healthcare) Limited
JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products with product footprint across Greater China, Southeast Asia and certain other countries. Its portfolio includes a wide range of branded healthcare products, comprising consumer healthcare products and proprietary Chinese medicines. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk

For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk
Stephanie Liu Tel: (852) 2864 4852 Email: stephanie.liu@sprg.com.hk
Adrianna Lau Tel: (852) 2114 4987 Email: adrianna.lau@sprg.com.hk
Fax: (852) 2527 1196


Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Heathrow Covid Chaos British Tech Co Has Solution

MANCHESTER, UK, Jan 22, 2021 – (ACN Newswire) – British tech company VST Enterprises (VSTE) warned airlines and the travel industry in December of last year of 'Covid related security threats' prior to the chaotic scenes that unfolded at Heathrow airport (Monday 18th Jan).











Tech boss and CEO Louis-James Davis warned of the very real and serious threats facing airlines, airports and passengers from fake Covid 19 test certificates, vaccination record cards, social distancing breaches and the use of health passports with 'un safe' QR and bar code technology. He also warned of the serious implications of potential data breaches using 'unsecure' code scanning technology in health passports.

Passengers arriving into the UK this week (Monday) were faced with unprecedented scenes at Heathrow airport with long delays, social distancing rules breached, altercations between passengers and border officials, GBP500 on the spot fines and passengers being refused entry to flights for holding invalid Covid 19 certificates. The chaos came as the British Government put in place tough new measures for entry into the UK in a bid to get a grip of the pandemic and prevent the further spread of infection. Passengers were required to provide verifiable proof of their Covid 19 negative test result.

VSTE developed and launched the worlds first secure digital health passport called V-Health Passport(TM) in April (2020) both for passengers and airlines which authenticates a persons health status including Covid test status and their vaccination records all within a secure digital passport. The V-Health Passport(TM) 'cross border' technology can be used across all air, land and sea transport infrastructure. The V-Health Passport(TM) has over 200 clinics across the UK where a person can book a Covid test – including a PCR based test – and be recognised as 'FIT TO FLY' by all International airlines. VSTE believes its solution can solve the global airline and travel issue.

V-Health Passport(TM) will shortly start its roll out program of secure health passport across number of airlines and airports globally. In the UK it has already started this programme and is available through its healthcare testing partners Salutaris People www.salutarispeople.com and Akea Life at www.akealife.co.uk both at Newcastle and Liverpool John Lennon airports.

Both healthcare partners also offer full airline travel Covid testing at their own clinics with PCR based testing for airline travel with a V-Health Passport(TM). They also supply 'home test kits' which are supervised over Zoom calls.

It is the first company in the world to have a fully functioning and secure LIVE health passport that carries a persons Covid test status and vaccination record in one secure app. Most importantly the technology is GDPR compliant and was built on a privacy framework of 'Self Sovereign Identity' where the person – or airline passenger – can choose what information they want to share, when they want to share it and with who. Privacy by design is at the forefront of the V-Health Passport(TM) framework unlike other health passport technologies.

V-Health Passport(TM) is a test and vaccine agnostic platform working with all Covid 19 protocols from PCR to rapid antigen and antibody tests which can also authenticate a persons vaccine immunisation record. V-Health Passport(TM) is also the most secure passport technology in the world unlike bar codes and QR codes which are subject to a process called 'Attagging' where a QR code can be cloned and faked. Using the VCode(R) cyber coding, it works on a 'closed loop' system with 'end-to-end' encryption and has over 2.2 Quintillion variations of codes that are subject to many scanning permissions making it impossible to hack the front or back end.

V-Health Passport(TM) is 10 seconds faster than any code scanner and can also be scanned within and outside of the safe social distancing of 2 metres, whereas bar codes and QR codes have to be scanned in close proximity of inches. In other circumstances it can also be scanned upto 100 metres away, allowing for easier crowd and queue ingress and egress.

In addition to the security flaws and close proximity of QR code scanning, another downfall of using QR Code for this type of passport solution is that a user may have to carry hundreds of different QR codes for the same identity use case. Companies who wish to add any form of extra security to the QR code would also have to offer their own app to scan a QR code which may lead to a consumer having to carry 100's of apps or codes due to the QR codes open source nature (not being generated from a central source).

Commenting on the chaos around the events at Heathrow, VSTE CEO Louis-James Davis said;

"The scenes at Heathrow could have been easily avoided by using a secure system such as V-Health Passport(TM). Both airports and the airlines need to move to a secure digital platform technology to ensure the security and faster processing of passengers to verify their Covid status and vaccination records. We have that technology now and it is available for airline passengers and the airlines to download and use today. By using the V-Health Passport(TM) technology a passengers valid Covid 19 test certificate could have been scanned further than the 2 metre safe social distancing protocols and upto 100 metres away. This would have allowed for a smooth ingress of passengers coming through border control into the UK verified against their identity. This would have also helped the passengers to maintain safe social distancing and a much quicker processing through border control thus avoiding the social breaches which occurred.

The V-Health Passport(TM) would not only provide border officials and airports with authentication of an airline passengers Covid 19 test status – with both a digital and printed PCR test certificate – but also their vaccination records. The technology also verifies a persons genuine identity against their existing Government ID adding another layer of security. There has been a phenomenal rise in the sale of 'Fake Covid' certificates, with both Russia and the Middle East seeing the greatest activity and posing a serious threat to global aviation security.

Using any open-source technology such as RFID, bar code or QR code with any form of health passport or vaccine card/certificate leads it wide open to being hacked or cloned with a person effectively making themselves 'permanently Covid negative' and 'permanently vaccinated' and allowing them to travel freely. By moving towards a secure 'one for all' technology based solution that passengers can use with their phones, will not only protect the data of passengers but also the safety of their health. It will ensure that a passenger who is travelling has a valid Covid test result or vaccine immunisation record and ensuring other fellow passengers are safe."

The V-Health Passport(TM) technology has a complete audit trail of a persons Covid testing, their vaccination records and the clinics where those tests or vaccinations have been conducted. This information is also protected under the 'Self Sovereign Identity' data framework allowing only the passenger to view this information, with officials only able to see a current and valid Covid 19 test or vaccine status in the GDPR display of the app.

With the alarming increase and black market trade in fake Covid 19 test certificates and also vaccination cards and certificates this also puts a very real threat and risk to passenger safety. It poses a threat to airlines and international borders with the potential for a passenger carrying a fake Covid test certificate or vaccination card – who may be asymptomatic – to board an aircraft and infect other passengers. This poses a very real threat to the aviation sector and to Governments around the world as they try to arrest the rate of infection.

It is well documented that bar codes and QR codes can be hacked so any airline who considers using a health passport for Covid 19 testing and vaccination using this method of authentication risks a serious potential breach of its passenger data. In 2018 British Airways was fined a record GBP20M for a data breach on 400,000 of its customers which affected their personal and credit card data. It now faces one of the biggest ever group privacy claims in UK legal history as reported in the Financial Times. It comes at a time when security over the use of bar codes and QR codes in airline travel has come under intense scrutiny following the cyber attack last year on the former Australian Prime Minister Tony Abbot. The former PM had his Qantas airline boarding pass hacked. Details including his passport, mobile phone and messages between Qantas staff about him were intercepted.

VSTE CEO Louis-James Davis added;

"We are the first technology company in the world to have developed a secure, multipurpose, cross corporate & cross government digital health passport that does not rely on using bar codes or QR codes as its authentication technology. Both bar codes and QR codes have huge potential security implications as they can be cloned and hacked with the latter being subject to a process called 'Attagging'. Therefore any suggestion of using this type of technology in a health passport for air travel has very real security risks. Not only is a citizen's personal information at risk, but their Covid test status, vaccination records and also their credit card information. All of this can lead to the very real potential of a massive data breach and a persons personal information and data hacked and stolen. This is of particular concern when using a bar code or QR code technology designed for use to authenticate a persons Covid 19 testing and/or vaccinations records."

Unlike other health passports, V-Health Passport(TM) has been designed with a citizens privacy front and centre. The technology does not track your live location and provides all data in a secure GDPR compliant framework giving citizens a unique 'self sovereign identity' style technology putting them in control of who, when and how they share their data.

Louis-James Davis went on to state that both bar codes and QR codes – which represent first and second generation technology – are unsecure and vulnerable to hacking.

"QR codes were originally developed as a scanning technology for close proximity car parts tracking, a world away from identity and banking use cases and now digital health passports. It was then used to skip the input of websites in marketing and promotional purposes. They were never designed with security or privacy in mind… they are simply not fit for purpose and should not be used at all in any form for delivery of sensitive information, travel or event tickets or health passport."

QR codes can be subject to a process called 'Attagging' or 'cloning.' The process of 'Attagging' is where a 'genuine QR code' is replaced by a 'cloned QR code' which then redirects the person scanning that code to a similar website where personal data can be intercepted and breached. The problem is that serious that in India alone there are over 1BILLION fraudulent financial transactions each day using QR codes. As the scanning user journey is the same, it is only tech savvy individuals that may notice the domain name has changed.

QR codes can be cloned and redirected to other information points or websites. Often criminals and hackers will exploit this by putting a fake QR code over a genuine QR code. So a QR code for example on scanning would link to the genuine website www.similardomain.com but a fake QR code can be made up printed off and placed over the genuine code to redirect to www.similar-domain.com at this point the member of the public is tricked into entering their personal information, private data and financial information. The rogue website looks and feels exactly like the genuine one and is made to mirror it precisely.

VCode(R) which is the ultra secure digital code which powers the V-Health Passport(TM) cannot be cloned. Even if it was printed off, or a photograph was taken and placed over a VCode(R) or V-Health Passport(TM) it simply won't scan as it works on a call and response system of information between the code and web platform to verify location of the code, user ID and time and date and much more.

V-Health Passport(TM) is making a significant contribution to the safety, mobility and return to work of the UK economy, helping businesses and employers return their staff to offices, factories and warehouses.

VSTE is working with the UK Government and a number of other Foreign Governments around the world to use its technology. The company is active in multiple industries and sectors including the maritime and aviation industries, construction and major infrastructure projects, as well as major national and international sporting events. V-Health Passport(TM) is also being used by a number of private Covid testing clinics, manufacturers and healthcare practices.

V-Health Passport(TM) is available on the Apple App Store and Google Play by searching for 'VPassport' and downloading to your device.

For more information on VCode(R) and VPlatform(R) technology please visit
https://www.vstenterprises.com

For more information on V-HEALTH PASSPORT(TM).
https://v-healthpassport.co.uk

For all media enquiries
Please contact Gerard Franklin – Head Of Communications & External Relations
M: 07885 388398 e: gerard@vstenterprises.com
VST Enterprises Ltd | The Lexicon | Mount Street | Manchester | M2 5NT

NOTES TO EDITORS

About the V-Health Passport(TM)
Search 'VPassport'
Apple App Store & Google Play
www.v-healthpassport.co.uk

Available on the Apple App Store and Goole Play by searching for 'VPassport' and downloading to your device.

– V-Health Passport(TM) can be scanned at a safe social distance of 1-2 metres and upto 100 metres away. QR code and Barcode technology has to be scanned inches away and as such breaches social distancing protocols.
– The V-Health Passport(TM) can authenticate a persons genuine Covid 19 test certificate – held in the secure health passport app and a printable version. The ultra-secure platform can now also hold vaccination records of all the major vaccination manufacturers which will be crucial in a person validating they have been vaccinated, the vaccine type, batch, dosage and date.
– V-Health Passport(TM) uses a persons official Government ID such as drivers licence, passport and cross matches against databases. It is then paired against a facial recognition 'Live Likeness' test to verify the persons genuine status.
– V-Health Passport(TM) is a test agnostic platform meaning it works with all Covid testing protocols from PCR based tests to rapid antigen and antibody. It has over 200 clinics across the UK on its app for passengers to book a Covid 19 test including a PCR based test approved for International airline travel.
– V-Health Passport(TM) can be scanned in a 170 degree arc, whilst a person is moving and thus ensures smooth ingress and egress,
– V-Health Passport(TM) It uses the worlds most secure cyber coding technology which works from a close loop system with end to end encryption and has over 2.2 Quintillion combination codes making it impossible to hack the front of back end of its system.
– V-Health Passport(TM) is a GDPR compliant technology built around self sovereign identity, allowing the airline passenger or member of the public to choose what data they want to share, with whom and when.
– V-Health Passport(TM) is available now and can be downloaded from the Apple App Store or Google Play by searching for 'VPassport' or by visiting www.v-healthpassport.co.uk.
– V-Health Passport(TM) also has its own unique contact tracing capability 'True Contact(TM)' built within the technology designed for travel, sports stadiums, venues, factories, offices and construction sites.
– V-Health Passport(TM) is the only health wallet and cross border platform in the world that is multi-functional and GDPR compliant. It allows acts like 'self sovereign identity', meaning a citizens personal data is protected and they choose what they want to share and with whom they want to interact or authorise.

SOURCE: VST Enterprises Ltd

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Citicode Ltd. Shareholders Approve Reverse Takeover of Homegrown Multi-Disciplinary Healthcare Specialist Livingstone Health Holdings Limited

SINGAPORE, Jan 22, 2021 – (ACN Newswire) – Shareholders of Citicode Ltd. ("Citicode" or the "Company") today approved the reverse takeover ("RTO") of homegrown multi-disciplinary healthcare specialist Livingstone Health, marking the start of a new chapter of growth in Singapore and across the Asia Pacific region.

At the extraordinary general meeting ("EGM"), shareholders of Citicode approved the RTO and the transfer of the Company's shares from the SGX Mainboard to the Catalist Board and change of corporate identity to Livingstone Health Holdings Limited ("Livingstone Health Holdings").

Livingstone Health Holdings has 15 medical doctors practising at 12 medical clinics and one medical spa located at various Singapore locations. It offers tertiary healthcare services such as aesthetics and wellness, anaesthesiology and pain management, internal medicine, orthopaedic surgery, and primary healthcare service such as family medicine, as well as other paramedical products and services including physiotherapy. It has formed a joint venture in Cambodia to provide aesthetics and wellness services, and also offers healthcare design consultancy services.

With a capital market platform, Livingstone Health Holdings plans to tap into the fast-growing healthcare sector by exploring other healthcare-related fields to complement its multi-disciplinary approach, and regional expansion via mergers and acquisitions, joint ventures and/or partnerships.

The successful EGM capped a combined new chapter for both Citicode and Livingstone Health. Citicode, under the leadership of its Executive Chairman and CEO Mr Teh Wing Kwan, had been seeking to transform the former Advance SCT Limited by evaluating growth strategies that led to a partnership with the medical group to offer integrated healthcare and engineering services. The partnership, in turn, led Mr Teh to consider the RTO, before negotiations commenced in late 2019.

Livingstone Health, previously known as Ardmore Medical Group Limited, had in 2019 withdrawn its proposal to list on the Catalist Board, citing developments related to its business operations at that time and changing market conditions. Under a new CEO, Dr Wilson Tay, it changed its name, increased specialisations and ventured into primary healthcare by acquiring a majority stake in homegrown family medicine service provider Phoenix Medical Group.

The reverse acquisition of Livingstone Health will be satisfied by a base and deferred consideration of S$47.0 million and up to S$25.0 million, respectively, of which up to S$2.0 million and up to S$1.5 million, respectively, will be in cash. New shares will be issued at S$0.20 per Consolidated Share.

The pro forma revenue and pro forma adjusted net profit after tax ("NPAT") of Livingstone Health were S$14.3 million and S$3.2 million, respectively, for FY2019. Unaudited revenue and net profit for the six months ended 30 June 2020 ("6M2020") were S$6.5 million and S$0.9 million, respectively.

Prior to the RTO, Citicode shares will first be consolidated on a 500-to-one basis, reducing its issued share base to approximately 82.6 million new Consolidated Shares from approximately 41.3 billion shares. After the RTO, Citicode share base will immediately be enlarged to approximately 315.9 million and up to 433.4 million by FY2022 upon issuance of base consideration shares and deferred consideration shares, respectively.

Voluntary trading suspension of Citicode shares is expected to start on 2 February 2021 to facilitate the expected completion of the RTO on 5 February 2021. Thereupon, the vendors comprising senior management and key doctors of Livingstone Health Holdings will be the new controlling shareholders of the Company.

Dr Wilson Tay will serve as Executive Director and CEO of Livingstone Health Holdings, while Mr Teh Wing Kwan, Citicode's current Executive Chairman and CEO, will be redesignated as Non-Executive and Non-independent Chairman and will remain as a substantial shareholder. The board of directors of the Livingstone Health Holdings will also include the existing Independent and Non-Executive Directors Mr Fong Heng Boo and Mr Chan Yu Meng and the newly appointed Mr Lim Jun Xiong Steven. The continued appointments of the existing board further underscore their confidence in the RTO.

Dr Tay said: "We thank Citicode's shareholders for supporting this transformation. The Livingstone Health team is excited by the growth opportunities. We are committed to delivering shareholder value through expansion in Singapore and the region, leveraging on our combination of primary and tertiary healthcare on a single platform which emphasises medical outcome and good governance."

Mr Teh Wing Kwan said: "The successful EGM marks the beginning of a new chapter of growth as a fast-growing healthcare services company poised to capture new opportunities at home and abroad with its brand of integrated healthcare. I thank shareholders of Citicode for their support of this corporate transformation."

SAC Capital Private Limited is the Financial Adviser in respect of the RTO and Sponsor of the Company upon the transfer to the Catalist Board.

Trading of the Company's shares, post-consolidation, is expected to resume trading on 8 February 2021, 9:00 am.

About Livingstone Health

Livingstone Health Ltd. ("Livingstone Health" and together with its subsidiaries, the "Group") is a Singapore-based multidisciplinary healthcare group whose core competencies include Aesthetics & Wellness, Anaesthesiology & Pain Management, Family Medicine, Internal Medicine and Orthopaedic Surgery.

The name "Livingstone" is inspired by the succulent plant Lithops, also known as "living stones". They symbolise the Group's resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence of growth opportunities for medical professionals.

The Group has 15 medical doctors practising at 12 medical clinics and one medical spa located at convenient and accessible locations throughout Singapore. In addition, the Group has also ventured into other paramedical products and services, such as physiotherapy. It has a joint venture to provide aesthetics and wellness services in Cambodia and also offers healthcare design consultancy services. For more information, please visit: www.livingstonehealth.com.sg

About Citicode Ltd. (SGX:5FH)

Listed on the Mainboard of the Singapore Exchange since 2004, Citicode Ltd. is the result of the business transformation and corporate rebranding of the former Advance SCT Limited in 2018. Citicode reflects the reimagined corporate identity composed by the new Board and management team.

Citicode has diversified into new business segments including M&E for mission critical functions, as well as civil and structural engineering for land transport infrastructure, with a view to form an ecosystem to support smart city applications while evaluating other strategic application plans.

Media & Investor Contact Information
WeR1 Consultants Pte Ltd
1 Raffles Place
#02-01 One Raffles Place Mall Suite 332
Singapore 048616
Isaac Tang, livingstone@wer1.net (M: +65 9748 0688)

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

HONG KONG, Jan 18, 2021 – (ACN Newswire) – SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011, an innovative third-generation covalent reversible Bruton's tyrosine kinase ("BTK") inhibitor drug candidate, today in Shuguan Hospital in Shanghai, China. The subject is currently in a normal condition.





Medical staff from Shuguan Hospital in Shanghai conducted the Phase I clinical trial of SN1011.



SN1011 is the third generation, covalent reversible Bruton's tyrosine kinase ("BTK") inhibitor designed for higher selectivity and superior efficacy for the long-term treatment of systemic lupus erythematosus, rheumatoid arthritis, pemphigus, multiple sclerosis and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of selectivity and affinity. The Phase I clinical trial was conducted in Shuguan Hospital in Shanghai, aiming to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and recommended Phase II dose of SN1011 in treatment for autoimmune diseases. SinoMab received the approval of SN1011's Investigational New Drug application ("IND") from the National Medical Products Administration of China on 27 August 2020, taking less than 5 months to progress into the current dosing stage, which utterly proves the Company's efficient implementation of new drug R&D programs.

Dr. Weian YUAN, Principal Investigator from Shuguan Hospital in Shanghai for this Phase I Study, said, "So far, there are a number of BTK inhibitors that have been approved, but there is no third-generation BTK inhibitor that is yet approved. Since the third generation BTK inhibitor has much lower effective dose and a better safety profile, it makes SN1011 a promising product to bring patients a much better treatment."

Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab, said, "SN1011 successfully completed its first dose, representing another key R&D asset entering the stage of clinical trial following our flagship product, SM03. This is a prominent milestone along SinoMab's progress in the R&D of various products for autoimmune diseases. Last year we launched the multiple ascending dose cohorts for SN1011 in Australia. SN1011, which shows great safety in clinical trials, possesses advantages of working just in a small dose and continuously benefitting patients, outperforming other BTK inhibitors in the market. We are absolutely confident in the enormous prospects of SN1011's clinical development. We will accelerate the program in the future, hoping to provide safe, effective and affordable drugs for patients suffering from autoimmune diseases around the world."

About SN1011
Bruton tyrosine kinase is a key kinase in the BCR signaling pathway in the B cell. Owing to the fact that loss of BTK exerts great impact on B cell development, targeting BTK becomes an attractive therapeutic means for autoimmune disease. SN1011 is a third generation BTK inhibitor which is covalent reversible in binding nature. It has unique chemical structure which renders it high binding affinity and selectivity towards BTK and excellent bioavailability in animal model. SN1011 has better efficacy and safety than other BTK inhibitors in pre-clinical studies. These data support the long-term usage for the treatment of autoimmune diseases in human.

About SinoMab BioScience Limited
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.


Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Jacobson Pharma’s Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited

HONG KONG, Jan 15, 2021 – (ACN Newswire) – Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced the declaration of a conditional special interim dividend by way of a distribution in specie of an aggregate of 241,777,625 JBM Shares, representing approximately 27.1% of the total number of JBM Shares in issue immediately upon completion of the proposed spin-off, to the qualifying shareholders.

As of today, the total number of issued shares of the Company ("Shares") is 1,934,221,000. Assuming there is no change in the total number of shares from today up to 29 January 2021 (the "Record Date"), the qualifying shareholders will receive one JBM Share for every eight Shares held on the Record Date.

The distribution is conditional on the public offer becoming unconditional in all respects. If such condition is not satisfied, the proposed spin-off will not take place and the distribution will not be made.

For more details, please refer to the link of announcement:
https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0115/2021011501333.pdf

About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group also carries a portfolio of proprietary brands, notably Po Chai Pills, Ho Chai Kung TjiThung San, Contractubex Scar Gel, Flying Eagle Woodlok Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet, which have been widely recognised by the market. In the strategic expansion of its branded healthcare business platform, the Group has introduced health and wellness brands and products such as Dr. Freeman Flu/RSV Combo, SmartfishHealth Nutrition Products, Dr. Freeman Infection Control Product Series and Dr Freeman COVID-19 Rapid Test Kit, among other reputable brands represented in overseas markets such as Excilor and Weisen-U.

The Group aims at the continued strategic enrichment of both of its generic drug and branded healthcare portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com

For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk
Rachel Ko Tel: (852) 2114 2370 Email: rachel.ko@sprg.com.hk
Mandy Wong Tel: (852) 2114 4900 Email: mandy.wong@sprg.com.hk
Fax: (852) 2527 1196


Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com